Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Schwind

Showing results (21-30 of 104) with videos related to

Pageof 11
Sort By:
American Journal of Hematology|September 10, 2019
Comparison of non-myeloablative and reduced-intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromesMadlen Jentzsch, Christine Döhring, Richard Linke, et al.
Cancers|November 27, 2021
Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell TransplantationDonata Backhaus, Madlen Jentzsch, Lara Bischof, et al.
Frontiers in Oncology|December 27, 2021
Case Report: Graft <i>Versus</i> Tumor Effect After Non-Myeloablative Allogeneic Stem-Cell Transplantation in a Patient With Brentuximab-Vedotin Refractory Sezary SyndromeGeorg-Nikolaus Franke, Konstantin Dumann, Madlen Jentzsch, et al.
Bone Marrow Transplantation|July 16, 2021
Measurable residual disease of canonical versus non-canonical DNMT3A, TET2, or ASXL1 mutations in AML at stem cell transplantationMadlen Jentzsch, Juliane Grimm, Marius Bill, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|December 17, 2016
Nanochannel Electroporation as a Platform for Living Cell Interrogation in Acute Myeloid LeukemiaXi Zhao, Xiaomeng Huang, Xinmei Wang, et al.
American Journal of Hematology|July 21, 2021
Clinical implications of SRSF2 mutations in AML patients undergoing allogeneic stem cell transplantationJuliane Grimm, Madlen Jentzsch, Marius Bill, et al.
Journal of Cancer Research and Clinical Oncology|October 2, 2015
Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantationChristian Pfrepper, Anne Klink, Gerhard Behre, et al.
Blood Cancer Journal|December 18, 2022
Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantationMadlen Jentzsch, Lara Bischof, Jule Ussmann, et al.
Transfusion|December 11, 2021
Stem-cell mobilization of healthy sibling donors with pegfilgrastim-A prospective open-label phase II trial (EudraCT no: 2005-004971-39)Vladan Vucinic, Madlen Jentzsch, Sabine Leiblein, et al.
Blood Advances|October 20, 2021
The diagnostic red blood cell distribution width as a prognostic factor in acute myeloid leukemiaVladan Vucinic, Leo Ruhnke, Katja Sockel, et al.
Pageof 11

Showing results (21-30 of 104) with videos related to

Sort By:
Pageof 11
American Journal of Hematology|September 10, 2019
Comparison of non-myeloablative and reduced-intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromesMadlen Jentzsch, Christine Döhring, Richard Linke, et al.
Cancers|November 27, 2021
Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell TransplantationDonata Backhaus, Madlen Jentzsch, Lara Bischof, et al.
Frontiers in Oncology|December 27, 2021
Case Report: Graft <i>Versus</i> Tumor Effect After Non-Myeloablative Allogeneic Stem-Cell Transplantation in a Patient With Brentuximab-Vedotin Refractory Sezary SyndromeGeorg-Nikolaus Franke, Konstantin Dumann, Madlen Jentzsch, et al.
Bone Marrow Transplantation|July 16, 2021
Measurable residual disease of canonical versus non-canonical DNMT3A, TET2, or ASXL1 mutations in AML at stem cell transplantationMadlen Jentzsch, Juliane Grimm, Marius Bill, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|December 17, 2016
Nanochannel Electroporation as a Platform for Living Cell Interrogation in Acute Myeloid LeukemiaXi Zhao, Xiaomeng Huang, Xinmei Wang, et al.
American Journal of Hematology|July 21, 2021
Clinical implications of SRSF2 mutations in AML patients undergoing allogeneic stem cell transplantationJuliane Grimm, Madlen Jentzsch, Marius Bill, et al.
Journal of Cancer Research and Clinical Oncology|October 2, 2015
Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantationChristian Pfrepper, Anne Klink, Gerhard Behre, et al.
Blood Cancer Journal|December 18, 2022
Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantationMadlen Jentzsch, Lara Bischof, Jule Ussmann, et al.
Transfusion|December 11, 2021
Stem-cell mobilization of healthy sibling donors with pegfilgrastim-A prospective open-label phase II trial (EudraCT no: 2005-004971-39)Vladan Vucinic, Madlen Jentzsch, Sabine Leiblein, et al.
Blood Advances|October 20, 2021
The diagnostic red blood cell distribution width as a prognostic factor in acute myeloid leukemiaVladan Vucinic, Leo Ruhnke, Katja Sockel, et al.
Pageof 11